Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The Metsera acquisition suggests Pfizer believes metabolic disease is a priority area to become a top-tier business we should watch Pfizers pipeline for new obesity/metabolism projects (possibly built via smaller partnerships)
This demonstrates that the injectable route produces body-wide regenerative enhancement rather than just local effects at the injection site
I have previously summarised the therapeutic pipeline for MASH (see links below) and in the past year we have seen the approval of Resmetirom, and now Semaglutide / ozempic is showing very impressive data in a Ph3 trial
A single bout of vomiting can deplete more potassium than an entire banana replaces
US$ 26.04
US$ 26.64
US$ 21.34
US$ 23.42
US$ 20.15
US$ 25.10
US$ 22.45
US$ 21.97
US$ 20.71
US$ 22.49
